1. Catalog
  2. Nodes
  3. a(PUBCHEM:11249342)

a(PUBCHEM:11249342)

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
11249342
Namespace
PUBCHEM
Namespace Version
None
Pattern
^\d+$

Appears in Networks 1

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and s levels: target engagement, tolerability and pharmacokinetics in humans v0.1.0

In-Edges 0

Out-Edges 12

a(PUBCHEM:11249342) causesNoChange p(HGNC:CFH) View Subject | View Object

and the complement control protein, factor H, were unaffected by Posiphen (26.1% and +23.7%, respectively). PubMed:22791904

Appears in Networks:

a(PUBCHEM:11249342) increases path(MESH:Nausea) View Subject | View Object

A 160 mg dose was associated with an increased incidence of nausea and vomiting (four subjects were nauseous and three vomited) PubMed:22791904

Appears in Networks:

a(PUBCHEM:11249342) causesNoChange path(MESH:Nausea) View Subject | View Object

Posiphen 80 mg was determined as the no observed adverse effect level (table 1). PubMed:22791904

Appears in Networks:

a(PUBCHEM:11249342) increases path(MESH:Vomiting) View Subject | View Object

A 160 mg dose was associated with an increased incidence of nausea and vomiting (four subjects were nauseous and three vomited) PubMed:22791904

Appears in Networks:

a(PUBCHEM:11249342) causesNoChange path(MESH:Vomiting) View Subject | View Object

Posiphen 80 mg was determined as the no observed adverse effect level (table 1). PubMed:22791904

Appears in Networks:

a(PUBCHEM:11249342) decreases p(HBP:"sAPP-alpha") View Subject | View Object

Specifically, Posiphen lowered sAPPa and sAPPb levels by 59.9% and 57.7%, respectively, assessed by the AlpaLisa assay, and by 34.1% and 34%, respectively, assessed by the MSD assay, in accordance with Posiphen’s proposed mechanism of action to inhibit APP expression. PubMed:22791904

Appears in Networks:

a(PUBCHEM:11249342) decreases p(HBP:"sAPP-beta") View Subject | View Object

Specifically, Posiphen lowered sAPPa and sAPPb levels by 59.9% and 57.7%, respectively, assessed by the AlpaLisa assay, and by 34.1% and 34%, respectively, assessed by the MSD assay, in accordance with Posiphen’s proposed mechanism of action to inhibit APP expression. PubMed:22791904

Appears in Networks:

a(PUBCHEM:11249342) decreases p(HGNC:MAPT) View Subject | View Object

In addition, Posiphen significantly reduced levels of t-s (74.1%, as assessed by the Innogenetics assay and 46.2%, as assessed by the AlphaLisa assay) and p-s (61%, as assessed by the Innogenetics assay). PubMed:22791904

Appears in Networks:

a(PUBCHEM:11249342) decreases p(HGNC:MAPT, pmod(Ph)) View Subject | View Object

In addition, Posiphen significantly reduced levels of t-s (74.1%, as assessed by the Innogenetics assay and 46.2%, as assessed by the AlphaLisa assay) and p-s (61%, as assessed by the Innogenetics assay). PubMed:22791904

Appears in Networks:

a(PUBCHEM:11249342) decreases p(HGNC:C3) View Subject | View Object

A significant lowering of pro-inflammatory, C3 (86.9%) and microglial activation markers, MCP-1 (87.5%) and YKL-40 (72.7%), was evident. PubMed:22791904

Appears in Networks:

a(PUBCHEM:11249342) decreases p(HGNC:CCL2) View Subject | View Object

A significant lowering of pro-inflammatory, C3 (86.9%) and microglial activation markers, MCP-1 (87.5%) and YKL-40 (72.7%), was evident. PubMed:22791904

Appears in Networks:

a(PUBCHEM:11249342) decreases p(HGNC:CHI3L1) View Subject | View Object

A significant lowering of pro-inflammatory, C3 (86.9%) and microglial activation markers, MCP-1 (87.5%) and YKL-40 (72.7%), was evident. PubMed:22791904

Appears in Networks:

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.